share_log

Shareholders in Zhongzhu Healthcare HoldingLtd (SHSE:600568) Have Lost 65%, as Stock Drops 16% This Past Week

Shareholders in Zhongzhu Healthcare HoldingLtd (SHSE:600568) Have Lost 65%, as Stock Drops 16% This Past Week

中珠醫療控股有限公司(上海證券交易所代碼:600568)的股東下跌了65%,上週股價下跌了16%
Simply Wall St ·  04/18 00:41

Statistically speaking, long term investing is a profitable endeavour. But unfortunately, some companies simply don't succeed. To wit, the Zhongzhu Healthcare Holding Co.,Ltd (SHSE:600568) share price managed to fall 65% over five long years. That's not a lot of fun for true believers. And some of the more recent buyers are probably worried, too, with the stock falling 32% in the last year. Shareholders have had an even rougher run lately, with the share price down 31% in the last 90 days.

從統計學上講,長期投資是一項有利可圖的舉措。但不幸的是,有些公司根本沒有成功。也就是說,中珠醫療控股有限公司, Ltd(上海證券交易所代碼:600568)的股價在漫長的五年中成功下跌了65%。對於真正的信徒來說,這並不是什麼好玩的。一些最近的買家可能也感到擔憂,該股去年下跌了32%。股東們最近的表現更加艱難,股價在過去90天中下跌了31%。

Since Zhongzhu Healthcare HoldingLtd has shed CN¥438m from its value in the past 7 days, let's see if the longer term decline has been driven by the business' economics.

由於中珠醫療控股有限公司在過去7天內已從其市值下跌了4.38億元人民幣,讓我們看看長期下跌是否是由該業務的經濟推動的。

Given that Zhongzhu Healthcare HoldingLtd didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business development. Shareholders of unprofitable companies usually desire strong revenue growth. Some companies are willing to postpone profitability to grow revenue faster, but in that case one would hope for good top-line growth to make up for the lack of earnings.

鑑於中珠醫療控股有限公司在過去十二個月中沒有盈利,我們將專注於收入增長,以快速了解其業務發展。無利可圖的公司的股東通常希望強勁的收入增長。一些公司願意推遲盈利以更快地增加收入,但在這種情況下,人們希望良好的收入增長來彌補收益不足。

Over half a decade Zhongzhu Healthcare HoldingLtd reduced its trailing twelve month revenue by 3.4% for each year. While far from catastrophic that is not good. With neither profit nor revenue growth, the loss of 11% per year doesn't really surprise us. We don't think anyone is rushing to buy this stock. Ultimately, it may be worth watching - should revenue pick up, the share price might follow.

在過去的五年中,中珠醫療控股有限公司過去十二個月的收入每年減少3.4%。雖然這遠非災難性,但這並不好。由於利潤和收入都沒有增長,每年11%的虧損並不令我們感到驚訝。我們認爲沒有人急於購買這隻股票。歸根結底,這可能值得關注——如果收入回升,股價可能會隨之上漲。

The graphic below depicts how earnings and revenue have changed over time (unveil the exact values by clicking on the image).

下圖描述了收入和收入隨時間推移而發生的變化(點擊圖片即可顯示確切的數值)。

earnings-and-revenue-growth
SHSE:600568 Earnings and Revenue Growth April 18th 2024
SHSE: 600568 2024 年 4 月 18 日收益和收入增長

This free interactive report on Zhongzhu Healthcare HoldingLtd's balance sheet strength is a great place to start, if you want to investigate the stock further.

如果你想進一步調查中珠醫療控股有限公司,這份關於中珠醫療控股有限公司資產負債表實力的免費互動報告是一個很好的起點。

A Different Perspective

不同的視角

While the broader market lost about 16% in the twelve months, Zhongzhu Healthcare HoldingLtd shareholders did even worse, losing 32%. However, it could simply be that the share price has been impacted by broader market jitters. It might be worth keeping an eye on the fundamentals, in case there's a good opportunity. Unfortunately, last year's performance may indicate unresolved challenges, given that it was worse than the annualised loss of 11% over the last half decade. Generally speaking long term share price weakness can be a bad sign, though contrarian investors might want to research the stock in hope of a turnaround. Shareholders might want to examine this detailed historical graph of past earnings, revenue and cash flow.

儘管整個市場在十二個月中下跌了約16%,但中珠醫療控股有限公司股東的表現甚至更糟,跌幅爲32%。但是,可能只是股價受到了更廣泛的市場緊張情緒的影響。如果有很好的機會,可能值得關注基本面。不幸的是,去年的表現可能預示着尚未解決的挑戰,因爲它比過去五年中11%的年化虧損還要糟糕。總的來說,長期股價疲軟可能是一個壞兆頭,儘管逆勢投資者可能希望研究該股以期出現轉機。股東們可能需要查看這張詳細的過去收益、收入和現金流的歷史圖表。

If you like to buy stocks alongside management, then you might just love this free list of companies. (Hint: insiders have been buying them).

如果你想與管理層一起購買股票,那麼你可能會喜歡這份免費的公司名單。(提示:業內人士一直在購買它們)。

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Chinese exchanges.

請注意,本文引用的市場回報反映了目前在中國交易所交易的股票的市場加權平均回報。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論